Emerging small molecule drugsColin, S., Chinetti-Gbaguidi, G., Kuivenhoven, J. A. & Staels, B., 2015, In : Handbook of Experimental Pharmacology. 224, p. 617-630 14 p.
Research output: Contribution to journal › Article › Academic › peer-review
Dyslipidaemia is a major risk factor for cardiovascular diseases. Pharmacological lowering of LDL-C levels using statins reduces cardiovascular risk. However, a substantial residual risk persists especially in patients with type 2 diabetes mellitus. Because of the inverse association observed in epidemiological studies of HDL-C with the risk for cardiovascular diseases, novel therapeutic strategies to raise HDL-C levels or improve HDL functionality are developed as complementary therapy for cardiovascular diseases. However, until now most therapies targeting HDL-C levels failed in clinical trials because of side effects or absence of clinical benefits. This chapter will highlight the emerging small molecules currently developed and tested in clinical trials to pharmacologically modulate HDL-C and functionality including new CETP inhibitors (anacetrapib, evacetrapib), novel PPAR agonists (K-877, CER-002, DSP-8658, INT131 and GFT505), LXR agonists (ATI-111, LXR-623, XL-652) and RVX-208.
|Number of pages||14|
|Journal||Handbook of Experimental Pharmacology|
|Publication status||Published - 2015|